Saturday 17 October 2026
Export XTLB’s income statement to Excel — free account
XTL Biopharmaceuticals Ltd.
XTLB Healthcare Biotechnology
1.96
0.05
+2.62%
Follow XTLB
XTL Biopharmaceuticals Ltd. (XTLB) P/E ratio
XTL Biopharmaceuticals Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 36.9× (August 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 36.9×
Ten-year median
0.0×
Current reading's percentile
81
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| IMRN IMMURON compare | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)